Skip to main content
OGN logo

OGN · Organon & Co.

Track OGN — free
$13.90 +0.00 (+0.00%) At close · Nov 17
Market Cap
$3.65B
Shares
262.62M
Volume · Nov 17 4.16M Avg daily vol (3M) 2.71M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$13.90 Open$13.90 Day$13.89–13.91 52W close$5.70–13.90 Avg vol 30d2.6M Short int19.7M · 7.5% of shares · 8.5d Short vol48% Last earningsApr 30, 2026 DataMay 2021–Nov 2026 Filing10-Q · Oct 30

Latest documents

2026
Oct 30
Current report 8-K
GAAP net income rose as adjusted earnings declined

Organon & Co. reported GAAP net income of $164 million for the quarter ended September 30, 2026, up from $160 million in 2025, while adjusted net income fell to $256 million from $263 million and adjusted EBITDA declined to $502 million from $518 million.

Regulation FD disclosure
5 source passages
On October 30, 2026, Organon & Co. (the “Company”) released its financial results for the quarter ended September 30, 2026 with the filing of the Company’s Quarterly Report on Form 10-Q (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”). Three Months Ended September 30, | 2026 | 2025 | Nine Months Ended September 30, GAAP Reported Net Income | 164 | 160 | 418 | 392 Non-GAAP Adjusted Net Income | 256 | 263 | 674 | 789 Adjusted EBITDA (Non-GAAP) | 502 | 518 | 1,378 | 1,524 Open the document at this passage
Oct 30
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Sun Pharma acquisition priced at $14.00 per share

Organon agreed to sell all outstanding shares to Sun Pharma for $14.00 per share in cash, with closing expected by early 2027. Worldwide sales were $1.6 billion for the three months ended September 30, 2026, down 2%.

Revenue $1.57B ▼ 1.7% Net income $164M ▲ 2.5% Diluted EPS $0.60 ▼ 1.6%
Read from the MD&A section
4 source passages
the possibility that competing offers or acquisition proposals for Organon will be made On April 26, 2026, we entered into a definitive agreement with Sun Pharma under which Sun Pharma will acquire all of our outstanding shares of common stock for $14.00 per share in cash. The transaction is expected to close by early 2027. Worldwide sales were $1.6 billion for the three months ended September 30, 2026, a decrease of 2%, compared to 2025. Open the document at this passage
Jul 31
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.56B ▼ 2.3% Net income $108M ▼ 25.5% Diluted EPS $0.40 ▼ 28.6%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$6.10B
Trailing 12 months
Net income (TTM)
$213.00M
Trailing 12 months
Revenue growth YoY
-1.7%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
18.1
Trailing earnings · reciprocal yield 5.5%
FCF yield
18.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$7.10B
Latest balance sheet
Dividend yield
0.7%
Trailing 12 months
Shares change YoY
+4.5%
Year over year · more shares
Price change (1Y)
+81.7%
Trailing year
Short interest
7.5%
Latest settlement · 8.5 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Bearish Fundamentals Fair Quant / Vol High
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +18%
above
Price vs 50-day avg +1%
above
RSI (14) 66
neutral
MACD trend Positive
52-week position 100%
near high
Momentum
relative strength
Very Strong
1-month return +1%
trailing
6-month return +4%
trailing
YTD return +94%
this year
Relative strength +7%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $14 › 200d $12 — 50d above 200d
Institutional flow Distributing
-6% holders QoQ · +50 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.50% of shares out · ▲ +4.7% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
616 holders — near 3-yr low, contrarian setup
Squeeze score 65
elevated · 0–100
Fundamentals
Fair
Revenue growth −3%
Y/Y
Gross margin 53%
contracting
EPS growth −78%
Y/Y
Free cash flow $538.0M
Valuation P/E 18.1
below peers
Balance sheet $8.1B
net debt
Quant / Vol
risk profile
High
Volatility 58%
annualized · 1-yr
Max drawdown −42%
past year
ATR 0.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 5
Latest guidance · from the 8-K filed Feb 12, 2026
Revenue · Full Year 2026 $6.2B
prior FY $6.22B midpoint −0.3% Y/Y
Adjusted EBITDA (non-GAAP) · Full Year 2026 Non-GAAP $1.9B
Guided vs delivered · last 5 settled
Revenue Full Year 2025
guided $6.28B – $6.38B
$6.22B Miss −1.7%
Revenues full-year 2024
guided $6.25B – $6.45B
$6.4B In line
Revenues Full Year 2023
guided $6.15B – $6.25B
$6.26B Beat +1.0%
Revenue Full year 2022
guided $6.1B – $6.4B
$6.17B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 2 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+18% Bullish
Price vs 50-day avg
+1% Bullish
RSI (14)
66 Neutral
MACD trend
Positive Bullish
52-week position
100% Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $14 › 200d $12 — 50d above 200d
Institutional flow Distributing
-6% holders QoQ · +50 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.50% of shares out · ▲ +4.7% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
616 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $6 Now $14 · 100% Range high $14
vs 200-day avg +18% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Bildyos/Bilprevda $19M the three months ended June 30, 2026 filing —
Brenzys $14M the three months ended June 30, 2026 filing —
Favorable foreign exchange impact on worldwide sales $42M the three months ended June 30, 2026 filing —
Ontruzant $6M the three months ended June 30, 2026 filing —
Zetia/Vytorin $118M the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
OGN
Organon & Co.
this stock
$3.65B +93.9% -2.9% 18.1 7.5%
LLY
ELI LILLY & Co
$1.33T +31.7% +44.7% 45.9 0.8%
JNJ
Johnson & Johnson
$670.92B +34.7% +6.0% 42.4 0.7%
ABBV
AbbVie Inc.
$517.59B +28.2% +8.6% 50.4 0.9%
MRK
Merck & Co., Inc.
$353.44B +36.2% +1.3% 147.8 1.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
616
% held
86.1%
Net QoQ
+7.5M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
307
View
Short & Settlement
Short Interest Rising
Shares short
19.7M
Days to cover
8.5d
Change
+876.3K sh
View
Short Volume
Short vol %
48%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
55
Value
$757
As of
Oct 19, 2026
View
Off-Exchange
Off-exchange %
46.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Kevin Hern
Amount
$1.0K–$15.0K
Traded
Aug 5, 2026
View
Financials
Financials
Revenue (FY)
$6.2B
Net income (FY)
$187.0M
EPS diluted
$0.72
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 30, 2026
This year
27

Organon & Co. reported GAAP net income of $164 million for the quarter ended September 30, 2026, up from $160 million in 2025, while adjusted net income fell to $256 million from $263 million and adjusted EBITDA declined to $502 million from $518 million.

View
Proposed Sales
Value
$200.3K
Shares
14.8K
Filed
Aug 5, 2026
View
Earnings & Events
Webcasts
Last webcast
Jun 9, 2026
View

Performance

5D 20D 120D MTD YTD
OGN +0.1% +1.0% +4.1% +0.4% +93.9%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY +2.4% +5.8% +7.1% +3.5% +86.5%

Capital returns

Latest dividend
$0.02 / share · ex Nov 9, 2026
Cut 92.9%
Paid (TTM)
$0.10 / share · 5 payouts
Dividend yield (TTM, derived)
0.72%
Full dividend history

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1821825 CUSIP 68622V106 13F (30d) 642 filings 554 filers Visit website Investor relations